3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
21
Phase 1
5
Phase 3
4
Phase NA
1
Phase 2/3
1
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
6
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Astrocytoma
2
Vipoma
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Progression Free Survival
1
Oropharyngeal Neoplasms
1
Oesophagogastric Cancer
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Mesothelioma
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Insulinoma
1
Inflammatory Breast Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Temozolomide
3
Gemcitabine
3
Etoposide
3
pembrolizumab
2
Rituximab
2
Lomustine
2
Haloperidol
2
Dexamethasone
2
Cyclosporine
2
vocimagene amiretrorepvec
1
trofosfamide
1
tinostamustine
1
selinexor
1
ruxolitinib
1
regorafenib
1
peginterferon alfa-2b
1
osimertinib
1
menatetrenone
1
interferon gamma-1b
1
interferon gamma, Cys(-3), Tyr(-2), Cys(-1)-
1
imetelstat
1
glumetinib
1
fludarabine
1
etoposide phosphate
1
eculizumab
1
dexamethasone acetate
1
dexamethasone 21-phosphate
1
carbon-11 acetate
1
blinatumomab
1
auricularum
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Recurrence
×
Bevacizumab
×
Clear all
NCT02414165
2020-02-07
Toca5
Tocagen Inc.
Phase 2/3
Terminated
403 enrolled